{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:54:37Z","timestamp":1791899677135,"version":"4.3.4"},"reference-count":10,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A woman with chronic hypoparathyroidism following total thyroidectomy was treated with palopegteriparatide, a long-acting parathyroid hormone replacement therapy, for more than 4 years. Previous reports have suggested that stopping parathyroid hormone therapy may lead to severe rebound hypocalcemia and increased calcium requirements due to a \u201chungry bone syndrome.\u201d After discontinuation of palopegteriparatide, the patient resumed conventional treatment with calcium supplements and active vitamin D at doses similar to those used before starting hormone therapy; the alfacalcidol dose was subsequently reduced because of high-normal calcium levels. She remained clinically stable without symptoms of hypocalcemia or hungry bone syndrome, and repeated blood tests showed normal calcium levels throughout follow-up. This case suggests that discontinuation of palopegteriparatide may not necessarily result in major disturbances in calcium balance or increased treatment requirements. The findings provide reassurance that some patients with chronic hypoparathyroidism can transition safely back to conventional therapy after long-term palopegteriparatide treatment.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag308","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:35:58Z","timestamp":1790076958000},"source":"Crossref","is-referenced-by-count":0,"title":["Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-4247","authenticated-orcid":false,"given":"Lars","family":"Rejnmark","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-1251","authenticated-orcid":false,"given":"Line","family":"Underbjerg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , 8200 Aarhus N ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"2","key":"2026101309335244300_luag308-B1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026101309335244300_luag308-B2","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.269","article-title":"Changes in treatment needs for chronic postoperative hypoparathyroidism during initiation of conventional treatment compared to stable phase of treatment","volume":"4","author":"Storm","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"2026101309335244300_luag308-B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2026101309335244300_luag308-B4","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026101309335244300_luag308-B5","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026101309335244300_luag308-B6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00223-014-9898-8","article-title":"Effects on calcium homeostasis of changing PTH replacement therapy of postoperative hypoparathyroidism from intact PTH to teriparatide: a case series","volume":"95","author":"Bislev","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2026101309335244300_luag308-B7","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.2555","article-title":"Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism","volume":"30","author":"Gafni","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026101309335244300_luag308-B8","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026101309335244300_luag308-B9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026101309335244300_luag308-B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-025-01432-3","article-title":"Rebound effect following the discontinuation of palopegteriparatide","volume":"116","author":"Naciu","year":"2025","journal-title":"Calcif Tissue Int"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag308\/71908382\/luag308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag308\/71908382\/luag308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:34:00Z","timestamp":1791898440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag308\/8914412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag308","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,25]]},"article-number":"luag308"}}